X

Trial Profile

A real-world, 2-year longitudinal study evaluating clinical effects of teriflunomide on fatigue and depression

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teriflunomide (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms TeriCARE

Most Recent Events

27 Apr 2023 Results of subanalysis assessing the effect of teriflunomide on clinical and patient-reported outcomes in disease-modifying therapy (DMT)-naive and previously treated (switch) patients with relapsing-remitting multiple sclerosis, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
15 Dec 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com